Photobiomodulation for Alzheimer’s Disease: Translating Basic Research to Clinical Application

Manuscript Number: 

19-1210R2

Author(s): 
Peter Dungel, Joachim Enengl, Michael R. Hamblin

Disclosures

Peter Dungel

  • Nothing to Disclose

Joachim Enengl

  • Nothing to Disclose

Michael R. Hamblin

  • Consulting Fees:
    Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; Medical Coherence, Boston MA; JOOVV Inc, Minneapolis-St. Paul MN; AIRx Medical, Pleasanton CA; UVLRx Therapeutics, Oldsmar, FL; Ultralux UV Inc, Lansing MI; Illumiheal & Petthera, Shoreline, WA; MB Lasertherapy, Houston, TX; ARRC LED, San Clemente, CA; Varuna Biomedical Corp. Incline Village, NV Consulting fees Lexington Int, Boca Raton, FL; USHIO Corp, Japan; Merck KGaA, Darmstadt, Germany; Philips Electronics Nederland B.V. Eindhoven, Netherlands; Johnson & Johnson Inc, Philadelphia, PA; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
    Equity:
    Global Photon Inc, Bee Cave, TX; Mitonix, Newark, DE.
    Patents/Royalties
    Expert witness White & Case LLP, New York, NY